“Geographic atrophy” is a medical term that refers to later-stage cases of dry age-related macular degeneration (AMD). Macular degeneration is an eye condition that affects the macula of your retina. This condition greatly impairs your central vision. You’ll still have your peripheral vision — what you can see on all sides of the center.
Typically, geographic atrophy affects both eyes (bilateral). If you have geographic atrophy, you’ll have blind spots (scotoma) in your central view, and you’ll lose some sharpness of vision.
More than 8 million people in the world have geographic atrophy. This figure represents about 20% of all the people who have age-related macular degeneration.
An estimated 1 million people in the U.S. have geographic atrophy.
Geographic atrophy is a late stage of macular degeneration. You might not notice symptoms in early stages or while the condition is in one eye only. When they do occur, geographic atrophy symptoms include:
Geographic atrophy is the last stage of dry age-related macular degeneration. Researchers don’t know the actual cause of the eye changes that lead to geographic atrophy, but they think your immune system (complement cascade) plays a role. Genetic and environmental factors also likely play a part.
Geographic atrophy isn’t contagious. You can’t give it to someone like you can pass on germs for some diseases.
There are risk factors for geographic atrophy. Risk factors make it more likely that a person will develop the condition.
Risk factors for geographic atrophy include:
Other risk factors include having conditions such as:
Vision loss due to geographic atrophy is, as of now, permanent. The loss of central vision can make it difficult to do some activities of daily living, including:
An eye care provider will diagnose geographic atrophy through a combination of a comprehensive eye examination and diagnostic tests. They’ll also ask you about your symptoms, medical history and family medical history.
During the eye examination, your provider will be able to recognize signs of geographic atrophy.
To diagnose geographic atrophy, your eye provider may order:
The U.S. Food and Drug Administration (FDA) recently approved the first medication to treat geographic atrophy. Pegcetacoplan (SYOFOVRE™) is a monthly, or every other month, intraocular injection that slows the progression of the disease.
Other ways of managing geographic atrophy include:
Pegcetacoplan injections are very new. Manufacturer literature suggests that these side effects are possible:
No. There’s no way to prevent geographic atrophy.
You may be able to lower your risk of developing geographic atrophy by addressing modifiable risk factors. Modifiable risk factors are things you can change, unlike age or ethnicity.
You may lower your risk by:
In general, the outlook for geographic atrophy hasn’t been good in terms of vision, but the disease progresses differently for each person. The outlook may be getting better, however, as there’s a new medication for treating geographic atrophy. Despite vision loss, the condition doesn’t affect life expectancy. Many people live full lives even with decreased vision.
Follow your eye care provider’s suggestions on how often you should have eye examinations. Be sure to keep track of any differences in how well you see.
Always see your provider if you experience sudden vision loss or eye pain. In those cases, you should get immediate medical help.
You’ll probably have many questions if you have geographic atrophy. You might want to ask your provider these types of questions:
A note from Cleveland Clinic
Geographic atrophy affects your central vision. It’s exciting that there’s a new treatment for geographic atrophy, and research into treatments is ongoing. But it can be difficult to accept a diagnosis for a condition that has had a poor outlook. Your eye care provider is someone who wants to help. Follow their suggestions. Ask all the questions you need to ask so you have the information that will allow you to live fully. There are many visual aids, techniques and services that you can use.